CHU de Nantes

Nantes, Pays de la Loire Region 44800

2 studies enrolling now · 2 studies all time

What they study most

ALK-positive Non-small Cell Lung Cancer (NSCLC), Non Small Cell Lung Cancer, ROS1-positive Non-Small Cell Lung Cancer (NSCLC)

Studies at this site

• Expanded Access Program of Neladalkib (NVL-655) for Patients With Advanced ALK+ NSCLC or Other ALK+ Solid Tumors — Available (expanded access)
• Expanded Access Program of Zidesamtinib (NVL-520) for Patients With Advanced ROS1+ NSCLC or Other ROS1+ Solid Tumors — Available (expanded access)